Floatz logo

Oxodotreotide

Stage III Thyroid Gland Medullary Carcinoma AJCC v8

M.D. Anderson Cancer Centerprotein_peptidePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Stage III Thyroid Gland Medullary Carcinoma AJCC v8 cohort.

Asset / SponsorPhaseRating
Selpercatinib
Eli Lilly and Company
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Tarlatamab
University of Arizona
Phase 2B
Everolimus
National Cancer Institute (NCI)
Phase 1CCC
Pralsetinib, trans-
Hoffmann-La Roche
Phase 1/2CCC

View all 36 →

Same molecule, other indications

Oxodotreotide is also rated in:

pancreatic neuroendocrine tumorDormant
BBB
Indicative ·
75 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Dormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →